In Vitro Activities of Mupirocin, Tigecycline, Ceftaroline, Vancomycin, Linezolid and Daptomycin in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus by E-Test Methodology


Introduction: In 2013, the Center for Disease Control (CDC) designated methicillin-resistant Staphylococcus aureus (MRSA) as a serious threat. In addition to its intrinsic virulence, MRSA has become resistant to numerous antibacterial agents. In many instances, mupirocin is used empirically to decolonize patients harboring MRSA to decrease the possibility of progression to disease. In vitro susceptibility information is critical to identify patients who would benefit from use of mupirocin for decolonization and treatment of infections caused by MRSA. Methods: One-hundred and sixty-three recent MRSA single patient clinical isolates were collected from the Clinical Microbiology Laboratory. In-vitro susceptibility testing was performed using E-test methodology for tigecycline, ceftaroline, daptomycin, vancomycin, linezolid, and mupirocin. Results: Of the 163 MRSA isolates tested, >99% demonstrated susceptibility to tigecycline, ceftaroline, daptomycin, vancomycin, and linezolid. Seventy (43%) had vancomycin MICs ≥ 1.5 μg/ml, twenty-four isolates (15%) were resistant to mupirocin, and three appeared to express mupirocin hetero-resistance. Conclusion: While antibiotic susceptibility to mupirocin is not routinely performed in clinical microbiology laboratories, the level of resistance to mupirocin identified in this surveillance study suggests that susceptibility testing should be added to routine MRSA panels.

Share and Cite:

Chadha, P. , Mariano, N. , LaBombardi, V. , Segal-Maurer, S. and Urban, C. (2015) In Vitro Activities of Mupirocin, Tigecycline, Ceftaroline, Vancomycin, Linezolid and Daptomycin in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus by E-Test Methodology. Open Journal of Medical Microbiology, 5, 12-16. doi: 10.4236/ojmm.2015.51002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Stryjewski, M.E. and Corey G.R. (2014) Methicillin-Resistant Staphylococcus: An Evolving Pathogen. Clinical Infectious Diseases, 58, S10-S19.
[2] Greenlee-Wacker, M., DeLeo, F.R. and Nauseef W.M. (in Press) How Methicillin-Resistant Staphylococcus aureus Evade Neutrophil Killing. Current Opinion in Hematology.
[3] CDC.
[4] Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A., Kallen, A., Limbago, B. and Fridkin, S. (2013) Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-1020. Infection Control Hospital Epidemiology, 34, 1-14.
[5] Clinical and Laboratory Standards Institute (2013) Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement. CLSI Document M100-S23, Clinical and Laboratory Standards Institute, Wayne.
[6] Cookson, B.D. (1998) The Emergence of Mupirocin Resistance: A Challenge to Infection Control and Antibiotic Prescribing Practice. Journal of antimicrobial Chemotherapy, 41, 11-18.
[7] Zimlichman, E., Henderson, D., Tamir, O., Franz, C., Song, P., Yamin, C.K., Keohane, C., Denham, C.R. and Bates, D.W. (2013) Healthcare-Associated Infections: A Meta-Analysis of Costs and Financial Impact on the US Health Care System. JAMA Internal Medicine, 173, 2039-2046.
[8] Scott, R.D. (2009) The Direct Medical Costs of Healthcare-Associated Infections in US Hospitals and the Benefits of Prevention.
[9] Sader, H.S., Fey, P.D., Fish, D.N., Limaye, A.P., Pankey, G., Rahal, J., Rybak, M.J., Snydman, D.R., Steed, L.L., Waites, K. and Jones, R.N. (2009) Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine US Medical Centers from 2002 to 2006. Antimicrobial Agents and Chemotherapy, 53, 4127-4132.
[10] Jacob, J.T. and DiazGranados, C.A. (2013) High Vancomycin Minimum Inhibitory Concentration and Clinical Outcomes in Adults with Methicillin-Resistant Staphylococcus aureus Infections: A Meta-Analysis. International Journal of Infectious Diseases, 17, e93-e100.
[11] Sakoulas, G., Moise-Broder, P.A., Schentag, J., Forrest, A., Moellering Jr., R.C. and Eliopoulos, G.M. (2004) Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Journal of Clinical Microbiology, 42, 2398-2402.
[12] Brink, A.J. (2012) Does Resistance in Se-vere Infections Caused by Methicillin-Resistant Staphylococcus aureus Give You the “Creeps”? Current Opinion in Critical Care, 18, 451-459.
[13] Bland, C.M., Porr, W.H., Davis, K.A. and Mansell, K.B. (2010) Vancomycin MIC Susceptibility Testing of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Isolates: A Comparison between Etest® and an Automated Testing Method. Southern Medical Journal, 103, 1124-1128.
[14] Arunava, K., Selvaraj, S., Sivaraman, U., Shailesh, K., Noyal, M.J. and Sreenivasan, S. (2013) Changing Trends in Resistance Pattern of Methicillin Resistant Staphylococcus aureus. Journal of Clinical and Diagnostic Research, 7, 1979-1982.
[15] Richter, S.S., Diekema, D.J., Heilmann, K.P., Dohrn, C.L., Crispell, E.K., Riahi, F., McDanel, J.S., Satola, S.W. and Doern, G.V. (2014) Activities of Vancomycin, Ceftaroline, and Mupirocin against Staphylococcus aureus Isolates Collected in a 2011 National Surveillance Study in the United States. Antimicrobial Agents and Chemotherapy, 58, 740-745.
[16] Lee, H., Lim, H., Bae, I.K., Yong, D., Jeong, S.H., Lee, K. and Chong, Y. (2013) Co-Existance of Mupirocin and Antiseptic Resistance in Methicillin-Resistant Staphylococcus aureus Isolates from Korea. Diagnostic Microbiology and Infectious Disease, 75, 308-312.
[17] Woodford, N., Afzal-Shah, M., Warner, M. and Livermore, D.M. (2008) In Vitro Activity of Retapamulin against Staphylococcus aureus Isolates Resistant to Fusidic Acid and Mupirocin. Journal of Antimicrobial Chemotherapy, 62, 766-768.
[18] Patel, J.B., Gorwitz, R.J. and Jernigan, J.A. (2009) Mupirocin Resistance. Clinical Infectious Diseases, 49, 935-941.
[19] Schweizer, M.L. and Herwaldt, L.A. (2012) Surgical Site Infections and Their Prevention. Current Opinion in Infectious Disease, 25, 378-384.
[20] van Rijen, M.M.L., Bonten, M., Wenzel, R.P. and Kluytmans, J.A.J.W. (2008) Intranasal Mupirocin for Reduction of Staphylococcus aureus Infections in Surgical Patients with Nasal Carriage: A Systematic Review. Journal of Antimicrobial Chemotherapy, 61, 254-261.
[21] Robotham, J.V., Graves, N., Cookson, B.D., Barnett, A.G., Wilson, J.A., Edgeworth, J.D., Batra, R., Cuthbertson, B.H. and Cooper, B.S. (2011) Screening, Isolation, and Decolonization Strategies in the Control of Methicillin Resistant Staphylococcus aureus in Intensive Care Units: Cost Effectiveness Evaluation. British Medical Journal, 343, Article ID: d5694.
[22] Courville, X.F., Tomek, I.M., Kirkland, K.B., Birhle, M., Kantor, S.R. and Finlayson, S.R.G. (2012) Cost-Effectiveness of Preoperative Nasal Mupirocin Treatment in Preventing Surgical Site Infection in Patients Undergoing Total Hip and Knee Arthroplasty: A Cost-Effectiveness Analysis. Infection Control and Hospital Epidemiology, 33, 152-159.
[23] Goldsack, J.C., DeRitter, C., Power, M., Spencer, A., Taylor, C.L., Kim, S.F., Kirk, R. and Drees, M. (2014) Clinical, Patient Experience and Cost Impacts of Performing Active Surveillance on Known Methicillin-Resistant Staphylococcus aureus Positive Patients Admitted to Medical-Surgical Units. American Journal of Infection Control, 42, 1039-1043.
[24] Huang, S.S., Septimus, E., Avery, T.R., Lee, G.M., Hickok, J., Weinstein, R.A., Moody, J., Hayden, M.K., Perlin, J.B., Platt, R. and Ray, G.T. (2014) Cost Savings of Universal Decolonization to Prevent Intensive Care Unit Infection: Implications of the REDUCE MRSA Trial. Infection Control Hospital Epidemiology, 35, S23-S31.
[25] Livermore, D.M. and Pearson, A. (2007) Antibiotic Resistance: Location, Location, Location. Clinical Microbiology and Infection, 13, 7-16.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.